Biomarker for senescent cells
US-2020371122-A1 · Nov 26, 2020 · US
Use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma
US9772324B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9772324-B2 |
| Application number | US-201414446298-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 29, 2014 |
| Priority date | Mar 23, 2007 |
| Publication date | Sep 26, 2017 |
| Grant date | Sep 26, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma. More particularly, the present invention relates to a pharmaceutical composition for treating asthma comprising BLT2 inhibitors and a method for treating asthma using BLT2 inhibitors.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for screening an agent for treating asthma, the method comprising the steps of: (a) contacting a lung cell or immune cell containing a long-form BLT2 gene or long-form BLT2 protein with an agent to be screened; and (b) measuring the expression or activity of long-form BLT2, wherein a decrease in the expression or activity of long-form BLT2 indicates the agent can be used for treating asthma, wherein the agent is an antibody or fragment thereof that specifically binds long-form BLT2.
Assignees
Inventors
Classifications
Special therapeutic applications · CPC title
involving specific cell types · CPC title
Double-stranded nucleic acids or oligonucleotides · CPC title
against receptors or cell surface proteins · CPC title
interfering nucleic acids [NA] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9772324B2 cover?
- The present invention relates to the use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma. More particularly, the present invention relates to a pharmaceutical composition for treating asthma comprising BLT2 inhibitors and a method for treating asthma using BLT2 inhibitors.
- Who is the assignee on this patent?
- Korea Univ Res & Business Found, Univ Korea Res & Bus Found
- What technology area does this patent fall under?
- Primary CPC classification G01N33/88. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Sep 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).